Mapping DNA methylation and chromatin features for better understanding of gene expression
Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping
This study is testing a new technology that helps scientists understand how changes in DNA can affect gene activity, which could lead to better ways to diagnose and treat diseases like cancer and neurological disorders, ultimately helping patients get more personalized care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Epicypher, INC. NIH-funded |
| Lab location | 1 site (Research Triangle Park, UNITED STATES) |
| Project ID | NIH-11006426 on NIH RePORTER |
What this research studies
This research focuses on developing a new technology called Targeted Enzymatic Methylation-sequencing (TEM-seqTM) to create detailed maps of DNA methylation and chromatin features. By using advanced techniques that require fewer cells and less sequencing effort, the project aims to uncover how changes in DNA methylation and chromatin structure influence gene expression. This could lead to better insights into various diseases, including cancers and neurological disorders, by providing a clearer picture of the molecular mechanisms involved. Patients may benefit from improved diagnostic tools and targeted therapies based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers or neurological disorders who may benefit from advanced genomic profiling.
Not a fit: Patients with conditions unrelated to DNA methylation or chromatin modifications may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostic tools and targeted treatments for various diseases, particularly cancers.
How similar studies have performed: Other research has shown promise in using multiomic approaches to understand gene regulation, indicating that this method could be a significant advancement in the field.
Where this research is happening
Research Triangle Park, UNITED STATES
- Epicypher, INC. — Research Triangle Park, United States (Active)
Researchers
- Principal investigator: Keogh, Michael-Christopher — Epicypher, INC.
- Study coordinator: Keogh, Michael-Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.